Nichols & Pratt Advisers LLP MA Grows Stake in IQVIA Holdings Inc. $IQV

Nichols & Pratt Advisers LLP MA raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 135,620 shares of the medical research company’s stock after purchasing an additional 3,964 shares during the period. IQVIA accounts for approximately 1.6% of Nichols & Pratt Advisers LLP MA’s investment portfolio, making the stock its 21st biggest holding. Nichols & Pratt Advisers LLP MA owned about 0.08% of IQVIA worth $26,204,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in IQVIA during the 4th quarter valued at about $27,000. Compass Financial Management LLC acquired a new stake in IQVIA in the second quarter worth about $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA during the fourth quarter worth about $27,000. CrossGen Wealth LLC purchased a new stake in shares of IQVIA during the fourth quarter worth about $28,000. Finally, Activest Wealth Management increased its holdings in shares of IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.7%

Shares of NYSE IQV opened at $260.48 on Friday. The firm has a market cap of $42.88 billion, a price-to-earnings ratio of 32.32, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18. The company’s 50-day simple moving average is $222.14 and its 200-day simple moving average is $189.62. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $265.25.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period last year, the company posted $2.81 EPS. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Insider Transactions at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This represents a 57.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 12,913 shares of company stock valued at $3,098,793 over the last ninety days. Company insiders own 1.70% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent analyst reports. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Royal Bank Of Canada upped their price target on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. TD Cowen raised their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Finally, Stifel Nicolaus upped their target price on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.